A tale of four studies: HIV vaccine immunogenicity and efficacy in clinical trials—Zolla-Pazner 2021

South Africa (HVTN 702) and Thailand (RV144) advanced-phase HIV prevention vaccination trials using canarypox vectors and adjuvanted gp120 proteins yielded diverse results. With the modified intention-to-treat analysis prespecified in both investigations, the Thai trial exhibited small but statistically significant vaccine efficacy, while the South African study did not. To prevent erroneously concluding that the South African study negatively impacted the Thai trial, one must grasp the contrasts between the research.

Zolla-Pazner, S., Michael, N. L., & Kim, J. H. (2021). A tale of four studies: HIV vaccine immunogenicity and efficacy in clinical trials. The lancet. HIV, 8(7), e449–e452. https://doi.org/10.1016/S2352-3018(21)00073-4